<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02623257</url>
  </required_header>
  <id_info>
    <org_study_id>20154701</org_study_id>
    <nct_id>NCT02623257</nct_id>
  </id_info>
  <brief_title>EGFR Mutations on ctDNA in Patients With Advanced NSCLC</brief_title>
  <official_title>A Diagnostic Study to Determine the Prevalence of Epidermal Growth Factor Receptor Mutations Assessed With Circulating Tumor DNA Samples in Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First People's Hospital of Hangzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First People's Hospital of Hangzhou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to explore the prevalence of EGFR mutations assessed with ctDNA samples in
      advanced NSCLC, who had received ≤ 1 prior systemic chemotherapy regimens.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with EGFR mutation detected by amplification refractory mutation system (ARMS) assay</measure>
    <time_frame>up to 2 years</time_frame>
    <description>The investigators will describe the proportion of EGFR mutation on ctDNA detected by ARMS assay in patients with non-small cell lung cancer (NSCLC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution of EGFR mutation by ARMS assays among the different Clinical characteristics</measure>
    <time_frame>up to 2 years</time_frame>
    <description>The investigators will employ chi-square test to analyze the distribution of EGFR mutation by ARMS in NSCLC patients among the different characteristics including smoking status, gender, age, PS score, and tumor stage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treatment-naive patients with EGFR mutation detected by amplification refractory mutation system (ARMS) assay</measure>
    <time_frame>up to 2 years</time_frame>
    <description>The investigators will describe the proportion of EGFR mutation on ctDNA detected by ARMS assay in treatment-naive patients with non-small cell lung cancer (NSCLC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients after first-line chemotherapy failure with EGFR mutation detected by amplification refractory mutation system (ARMS) assay</measure>
    <time_frame>up to 2 years</time_frame>
    <description>The investigators will describe the proportion of EGFR mutation on ctDNA detected by ARMS assay in non-small cell lung cancer (NSCLC) patients after first-line chemotherapy failure</description>
  </secondary_outcome>
  <enrollment type="Actual">1055</enrollment>
  <condition>Non-small Cell Lung Cancer Stage III</condition>
  <condition>Non-Small-Cell Lung Cancer Metastatic</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mutation detection</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ARMS</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>ctDNA analysis</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Non-small cell lung cancer (NSCLC)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed stage IIIB/IV NSCLC;

          -  Patient had received ≤ 1 prior systemic chemotherapy regimens;

          -  Provision of blood (plasma) sample for ctDNA testing;

          -  Patient must be able to comply with the protocol;

        Exclusion Criteria:

          -  Prior received ≥2 systemic chemotherapy regimens;

          -  As judged by the investigator, any evidence of severe or uncontrolled systemic disease
             (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease);

          -  Histologically confirmed small cell lung cancer or other metastatic tumors;

          -  Patient with no histologic or cytological diagnosis;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hangzhou First People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2015</study_first_submitted>
  <study_first_submitted_qc>December 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2015</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>circulating tumor DNA</keyword>
  <keyword>amplification refractory mutation system</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

